Silexion Therapeutics Corp. ( SLXN ) revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.

The additional preclinical data show that SIL-204 exhibits significant synergistic activity with 5-fluorouracil and irinotecan — two main components commonly used in pancreatic cancer treatments — when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in pancreatic cancer.

Also Read: Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies

Synergistic activity was also observed with the chemotherapeutic agent gemcitabine.

Synergistic activity was observed after the confluence of these tumor cell lines, reflecting how SIL-204 may enhance the effects of 5-fluorouracil and irinotecan when used together, as well as that of gemcitabine. 

In preclinical models, combining 5-fluorouracil and irinotecan with SIL-204 led to a significant reduction in cancer cell confluence after about three days compared to treatment with the chemotherapy agents alone. 

Silexion is planning to initiate toxicology studies with SIL-204 within the upcoming months and to advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC).

In parallel, the company plans to initiate preclinical studies for SIL-204 in colorectal cancer models.

Concurrently, Silexion Therapeutics ( SLXN ) priced a public offering of 3.7 million shares and warrants to purchase up to 3.7 million shares at a combined price of $1.35 per share and accompanying warrant, with gross proceeds of $5 million.

SLXN Price Action: SLXN stock is down 42.96% at 89 cents at publication Thursday.

Read Next:

Bank of America Q4 Earnings: $6.7 Billion Profit, $1.7 Billion In Investment banking fees, Forecasts Higher NII In 2025